• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS)

  • Print
  • Share
  • E-mail
-

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


             

ODE Lead-TRYTON Side Branch Stent EA Confirmatory


Suggest Enhancement / Report Issue | export reports to excelExport to Excel
General
Study Status Progress Adequate
Application Number P150039 / PAS002
Date Current Protocol Accepted  
Study Name ODE Lead-TRYTON Side Branch Stent EA Confirmatory
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source New Data Collection
Comparison Group Objective Performance Criterion
Analysis Type Analytical
Study Population Adult: >21
Detailed Study Protocol Parameters
Study Design Description TRYTON Extended Access (EA) Confirmatory Study - a non-randomized, single arm extension of the TRYTON Pivotal RCT. Subjects were implanted with the TRYTON Side Branch Stent with main branch approved DES for treatment of native coronary artery bifurcation disease.



Study Population Description N = 133 TRYTON patients
Sample Size 127 subjects yields 90% power to reject the following null hypothesis in favor of the corresponding alternative hypothesis:

• H0: pTRY greater than or equal to 0.179 (or 17.9%)

• H1: pTRY less than 0.179 (or 17.9%)

Where pTRY is the primary endpoint rate in the DES+TRYTON. Six additional subjects to be enrolled to account for an expected 4% loss to follow-up before the primary endpoint was measured, so the total enrolled sample size was planned to be 133. Enrolling 127 subjects affords 90% power to compare the primary endpoint rate from the EA Study to a performance goal of 17.9%, assuming a true endpoint rate of 8.9% for DES+TRYTON.



Data Collection Primary endpoint: Periprocedural MI defined as PCI CK-MB elevation with value >3 times the upper range limit within the first 48 hours after PCI.



Key secondary endpoints included all-cause mortality, Major Adverse Cardiac Events (MACE), and rates of stent thrombosis using the ARC definition.



Follow-up Visits and Length of Follow-up 1 year post-index procedure





ODE Lead-TRYTON Side Branch Stent EA Confirmatory Schedule

Report Schedule
Report
Date Due
FDA Receipt
Date
Applicant's Reporting Status
Final Report 08/22/2017 06/01/2017 On Time


Contact Us

Julie Unger
Project Manager, Post-Approval Studies Program
Food and Drug Administration
10903 New Hampshire Ave
WO66-4206v Silver Spring, MD
20993-0002

Phone: (301) 796-6134
Fax: (301) 847-8140
julie.unger@fda.hhs.gov

Related Links

-
-